Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Control (Diphenhydramine) Clear all
Recruiting Phase 2 Interventional

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

NCT06748404
View directory record Official record
Conditions
Immunotherapy-related Pruritus
Interventions
TriCalm Hydrogel®, Triamcinolone acetonide 0.1% cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

NCT02935699
View directory record Official record
Conditions
Acute Urticaria
Interventions
Test Drug (JDP-205), Active Control (Diphenhydramine)
Drug
Lead sponsor
JDP Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

NCT01411124
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
gabapentin enacarbil, diphenhydramine, placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 20, 2026, 10:48 AM EDT
Recruiting Phase 3 Interventional

Novel Strategies for Reducing Burn Scar Itch

NCT06801626
View directory record Official record
Conditions
Burn Scar, Itch Scarring, Wound
Interventions
Famotidine and 4% topical cromolyn sodium, Placebo
Combination Product · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Results available

Olmesartan Comparison to Losartan in Hypertensive Subjects

NCT00949884
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Placebo, losartan potassium
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • Harbor City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

NCT04175834
View directory record Official record
Conditions
Multiple Sclerosis, Infusion Reaction
Interventions
cetrizine, diphenhydramine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 20, 2026, 10:48 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 4 Interventional

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

NCT00648973
View directory record Official record
Conditions
Nasal Congestion
Interventions
Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
sparsentan, Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
87
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 73 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Results available

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Hydrochlorothiazide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

NCT01048866
View directory record Official record
Conditions
Pharyngitis
Interventions
placebo, flurbiprofen, acetaminophen 650mg
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Sep 20, 2026, 10:48 AM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

NCT00635232
View directory record Official record
Conditions
Hypertension
Interventions
irbesartan, placebo, PS433540
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Pell City, Alabama • Tempe, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 20, 2026, 10:48 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

NCT03657810
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 5 mg, Norco, Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 20, 2026, 10:48 AM EDT
Terminated Phase 1 Interventional Results available

Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms

NCT02846883
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
1 million MSCs/kg, 3 million MSCs/kg, Placebo
Biological · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 20, 2026, 10:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

NCT04294459
View directory record Official record
Conditions
Immune System Disorder
Interventions
Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 20, 2026, 10:48 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial

NCT01892995
View directory record Official record
Conditions
Suicide
Interventions
Ketamine
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 20, 2026, 10:48 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
sparsentan, irbesartan, Dapagliflozin
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Allo HSCT Using RIC for Hematological Diseases

NCT02661035
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions
Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 20, 2026, 10:48 AM EDT
Recruiting Phase 1 Interventional

Losartan + Sunitinib in Treatment of Osteosarcoma

NCT03900793
View directory record Official record
Conditions
Osteosarcoma
Interventions
Losartan, Sunitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 20, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Results available

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

NCT00153062
View directory record Official record
Conditions
Stroke
Interventions
Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
20,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
204
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Sep 20, 2026, 10:48 AM EDT